Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in laryngeal cancer

Anticancer Research

Volumn 27, Issue 1 A, 2007, Pages 335-342

  Pastuszewski, Wojciech ^a   Dziegiel, Piotr ^b   Krecicki, Tomasz ^c   Podhorska Okolow, Marzena ^b   Ciesielska, Urszula ^b   Gorzynska, Elzbieta ^d   Zabel, Maciej ^b  

^a NZOZ Ziemo Vita Medical Centre Ltd   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d J Babinski Voivodship Hospital in Wroclaw   (Poland)

Author keywords

Ki 67; Laryngeal cancer; Metallothionein; p53

Indexed keywords

KI 67 ANTIGEN; METALLOTHIONEIN; PROTEIN P53;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; CELL NUCLEUS; CYTOPLASM; FEMALE; HUMANS; KI-67 ANTIGEN; LARYNGEAL NEOPLASMS; MALE; METALLOTHIONEIN; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33847660185     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Ferlay J, Bray F, Pisani P and Parkin DM: GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, ver. 2.0, IARC Press, Lyon, 2004.
2. Almadori G, Bussu F, Cadoni G, Galli J, Paludetti G and Maurizi M: Molecular markers in laryngeal squamous cellcarcinoma: towards an integrated clinicobiological approach. Eur J Cancer 41: 683-693, 2005.
3. Ronchetti D, Neglia CB and Cesana BM:Association between p53 gene mutations and tobacco and alcohol exposure in laryngeal squamous cell carcinoma. Arch Otolaryngol 130: 303-306, 2004.
4. Frable WJ and Frable MAS: The larynx and trachea. In: Principles and Practice of Surgical Pathology. Silverberg SG (ed.). New York, Churchill Livingstone, pp. 503-520, 1988.
5. Makowska W, Malejczyk M, Kapiszewska D, Nyckowska J, Wójcikiewicz E and Wróblewska B: Wirusy brodawczakow ludzkich (HPV) wraku krtani. Otolaryngol Pol LV: 263-266, 2001.
6. Qadeer MA, Colabianchi N and Vaezi MF: Is GERD a risk factor for laryngeal cancer? Laryngoscope 115: 486-491, 2005.
7. Krecicki T, Jelen M, Zalesska-Krecicka M, Rak J, Szkudlarek T and Jelen-Krzeszewska J: Ki-67 immunostaining and prognosis in laryngeal cancer. Clin Otolaryngol All 23: 539-542, 1998.
8. Lera J, Lara PC, Perez S, Cabrera JL and Santana C: Tumor proliferation, p53 expression, and apoptosis in laryngeal carcinoma. Relation to the results of radiotherapy. Cancer 83: 2493-2501, 1998.
9. Sittel C, Eckel HE, Damm M, von Pritzbuer E and Kvasnicka HM: Ki-67 (MIB1), p53, and Lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2 laryngeal carcinoma. Laryngoscope 110: 1012-1017, 2000.
10. Kägi JHR and Schäffer A: Biochemistry of Metallothionein. Biochemistry 27: 8509-8515, 1988.
11. Dziegiel P: Expression of metallothioneins in tumor cells. Pol J Pathol 55: 3-12, 2004.
12. Cai L, Satoh M, Tohyama C and Cherian MG: Metallothionein in radiation exposure: its induction and protective role. Toxicology 132: 85-98, 1999.
13. Cherian MG, Jayasurya A and Bay B-H: Metallothioneins in human tumors and potential roles in carcinogenesis. Mutation Res 533: 201-209, 2003.
14. Goncharowa EI and Rossman TG: A role for metallothionein and zinc in spontaneous mutagenesis. Cancer Res 54: 5318-5323, 1994.
15. Jayasurya A, Bay BH, Yap WM and Tan NG: Correlation of metallothionein expression with apoptosis in nasopharyngeal carcinoma. Brit J Cancer 82: 1198-1203, 2000.
16. Jayasurya A, Bay BH, Yap WM and Tan NG: Proliferative potential in nasopharyngeal carcinoma: correlation with metallothionein expression and tissue zinc levels. Carcinogenesis 21: 1809-1812, 2000.
17. Mitropoulos D, Kyroudi-Voulgari A, Tcheocharis S, Serafetinides E, Moraitis E, Zervas A and Kittas C: Prognostic significance of metallothionein expression in renal cell carcinoma. World J Surg Oncol 17: 5, 2005.
18. Theocharis S, Karkantaris C, Philipides T, Agapitos E, Gika A, Margeli A, Kittas C and Koutselinis A: Expression of metallothionein in lung carcinoma: correlation with histological type and grade. Histopathology 40: 143-151, 2002.
19. Dziegiel P, Salwa-Zurawska W, Zurawski J, Wojnar A and Zabel M: Prognostic significance of augmentem metallothionein (MT) expression correlated with Ki-67 antigen expression in selected soft tissue sarcomas. Histol Histopathol 20: 83-89, 2005.
20. Jones AS, Roland NJ, Caslin AW, Cooke TG, Cooke LD and Forster G: A comparison of cellular proliferation markers in squamous cell carcinoma of the head and neck. J Laryngol Otol 108: 859-864, 1994.
21. Vielba R, Bilbao J, Ispizua A, Zabalza I, Alfaro J, Rezola R, Moreno E, Elorriaga J, Alonso I, Baroja A and de la Hoz C: p53 and cyclin D1 as prognostic factors in squamous cell carcinoma of the larynx. Laryngoscope 113: 167-172, 2003.
22. Harlozinska A, Bar JK, Sedlaczek P and Gerber J: Expression of p53 protein and Ki-67 reactivity in ovarian neoplasms. Correlation with histopathology. Am J Clin Pathol 105: 334-340, 1996.
23. Slootweg PJ, Koole R and Hordijk G: The presence of p53 protein in relation to Ki-67 as cellular proliferation marker in head and neck squamous cell carcinoma and adjacent dysplastic mucosa. Eur J Cancer B Oral Oncol 30B: 138-141, 1994.
24. Agaoglu FY, Dizdar Y, Dogan O, Alatli C, Ayan I, Savci N, Tas S, Dalay N and Altun M: p53 overexpression in nasopharyngeal carcinoma. In Vivo 18: 555-560, 2004.
25. Klatka J: Prognostic value of the expression of p53 and bcl-2 in patients with laryngeal carcinoma. Eur Arch Otorhinolaryngol 258: 537-541, 2001.
26. Remmele W and Stegner HE: Vorschlag zur eincheitlichen Definition eines Immunoreaktiven Score (IRS) für den immunohistochemischen Ostrogenrezeptor-Nachweis (ER - ICA) im Mammakarzinomgewebe. Der Pathologe 8: 138-140, 1987.
27. Bartel-Friedrich S, Friedrich RE, Lautenschlager C, Holzhausen HJ and Roser K: Expression and distribution of basement membrane proteins in rat larynx and trachea following irradiation. Anticancer Res 23: 877-884, 2003.
28. Brady FO: The physiological function of metallothionein. Trends Biochem Sci 7: 143-145, 1982.
29. Cherian MG, Huang PC, Klaassen CD, Liu YP, Longfellow DG and Waalkes MP: National Cancer Institute Workshop on the possible roles of metallothionein in carcinogenesis. Cancer Res 53: 922-925, 1993.
30. Jasani B and Schmid KW: Significance of metallothionein overexpression in human tumours. Histopathology 31: 211-214, 1997.
31. Fan LZ and Cherian MG: Potential role of p53 on metallothionein induction in human epithelial breast cancer cells. Brit J Cancer 9: 1019-1026, 2002.
32. Ioachim E, Assimakopoulos D, Peschos D, Zissi A, Skevas A and Agnantis NJ: Immunohistochemical expression of metallothionein in benign premalignant and malignant epithelium of the larynx: correlation with p53 and proliferative cell nuclear antigen. Pathol Res Pract 195: 809-814, 1999.
33. Ohshio G, Imamura T, Okada N, Wang Z.H, Yamaki K, Kyogoku T, Suwa H, Yamabe H and Imamura M: Immunohistochemical study of metallothionein in pancreatic carcinoma. J Cancer Res Clin 122: 351-355, 1996.
34. McCluggage WG, Maxwell P, Hamilton PW and Jasani B: High metallothionein expression is associated with features predictive of aggressive behaviour in endometrial carcinoma. Histopathology 34: 51-55, 1999.
35. Saga Y, Hashimoto H, Yachiku S, Tokumitsu M and Kaneko S: Immunohistochemical expression of metallothionein in human bladder cancer: correlation with histopathological parameters and patient survival. J Urol 168: 2227-2231, 2002.
36. Tuzel E, Kirkali Z, Yorukoglu K, Mungan MU and Sade M: Metallothionein expression in renal cell carcinoma: Subcellular localization and prognosis significance. J Urol 165: 1710-1713, 2001.
37. Brown JJ, Xu H, William-Smith L, Mohamed H, Teklehaimanot S, Zhuo J, Osborne R, Liu F, Gowans RE, Nishitani J and Liu X: Evaluation of metallothionein and p53 expression as potential prognostic markers for laryngeal squamous cell carcinoma. Cell Mol Biol 49: 473-479, 2003.
38. Ioachim EE, Goussia AC, Agnantis NJ, Machera M, Tsianos EV and Kappas AM: Prognostic evaluation of metallothionein expression in human colorectal neoplasms. J Clin Pathol 52: 876-879, 1999.
39. Oyama T, Takei H, Hikino T, lino Y and Nakajima T: Immunohistochemical expression of matallothionein in invasive breast cancer in relation to proliferative activity, histology and prognosis. Ocology 53: 112-117, 1996.
40. Dziegiel P, Forgacz J, Suder E, Surowiak P, Kornafel J and Zabel M: Prognostic significance of metallothionein expression in correlation with Ki-67 expression in adenocarcinomas of large intestine. Histol Histopathol 18: 401-407, 2003.
41. Spafford MF, Koeppe J, Pan Z, Archer PG, Meyers AD and Franklin WA: Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Acat Otolaryngol Head Neck Surg 122: 627-632, 1996.
42. Acikalin MF, Oner U, Tel N, Pasaoglu O, Cakli H and Colak E: Prognostic significance of Ki-67 expression for patients with laryngeal squamous cell carcinoma primarily treated by total laryngectomy. Eur Arch Otorhinolaryngol 261: 376-380, 2004.
43. Siu LL, Banerjee D, Khurana RJ, Pan X, Pflueger R, Tannock IF and Moore MJ: The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Clin Cancer Res 4: 559-565, 1998.
44. Miranda A, Janssen L, van Duijn W, Kubben FJ, Griffioen G, Lamers CB, van Krieken JH, van de Velde CJ and Verspaget HW: Prognostic significance of metallothionein in human gastrointestinal cancer. Clin Cancer Res 8: 1889-1896, 2002.
45. Yamamoto M, Tsujinaka T, Shiozaki H, Doki Y, Tamura S, Inoue M, Hirao M and Monden M: Metallothionein expression correlates with the pathological response of patients with esophageal cancer undergoing preoperative chemoradiation therapy. Oncology 56: 332-337, 1999.